<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193788</url>
  </required_header>
  <id_info>
    <org_study_id>KCSG GU16-05</org_study_id>
    <nct_id>NCT03193788</nct_id>
  </id_info>
  <brief_title>Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy</brief_title>
  <acronym>PREMIER</acronym>
  <official_title>A Prospective Randomized Phase III Trial of Maintenance Pemetrexed Versus Observation in Patients With Recurrent or Metastatic Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Without Disease Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korean Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to verify superiority of pemetrexed maintenance to observation for patient
      without disease progression after 1 st line cisplatin-based chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with unresectable locally advanced, recurrent, or metastatic urothelial carcinoma of
      bladder, ureter, or renal pelvis who do not experience disease progression after 4 to 6
      cycles of 1 st line chemotherapy administration.

      After completion of 4-6 cycles, patients without disease progression on CT which is taken
      within 3 weeks after administration of the last chemotherapy will be randomized within 4
      weeks after administration of the last chemotherapy to assign either maintenance group or
      observation group.

      Pemetrexed 500 mg/m 2 mixed in normal saline 100 mL as a 10 minute IV infusion on day 1 of
      each 21 day cycle, with vitamin supplementation (folic acid 1000μg daily orally from 7 days
      prior to treatment initiation and vitamin B12 1000 μg IM 7 days prior to treatment initiation
      and then every 3 cycles). Thereafter, vitamin B12 can be injected on the same day of
      pemetrexed infusion. Dexamethasone 4 mg orally twice daily for 3 days beginning the day
      before treatment to minimize cutaneous reactions.

      Treatment continues until occurrence of disease progression or intolerable toxicities upto
      maximum of 16 cycles.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>Every 9 weeks, from date of randomization until the date of first documented progression upto 24 months</time_frame>
    <description>Time between randomization and disease progression or death from any causes, whichever came first. Alive patients free of progression will be censored at the last follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>every 9 weeks, assess the best overall response from date of randomization until the date of first documented progression upto 24 months</time_frame>
    <description>Objective response rate will be measured according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>every 3 weeks for pemetrexed group, every 9 weeks for observation group from date of randomization until the date of first documented progression upto 24 months</time_frame>
    <description>Safety assessed per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 1 year after the end of treatment</time_frame>
    <description>Time interval between randomization and death (all causes). Alive patients will be censored at the last date of news or data cut off</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>before randomization, then 9, 18, and 27 weeks after randomization</time_frame>
    <description>QoL will be assessed by EORTC QLQ-C30 core questionaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Ureter Cancer</condition>
  <condition>Transitional Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>pemetrexed maintenance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Pemetrexed Maintenance therapy: 500 mg/m^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.
Drug: folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment
Drug: vitamin B12 injection 1000 μg IM 7 days prior to treatment initiation and the every then every 3 cycles until the end of treatment
Drug: dexamethasone 4 mg twice orally for 3 days beginning the day before treatment until the end of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>observation group will be observed with best supportive care until progressive disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed</intervention_name>
    <description>Pemetrexed 500 mg/m2mixed in normal saline 100 mL as a 10 minute IV infusion on day 1 of each 21 day cycle</description>
    <arm_group_label>pemetrexed maintenance</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment</description>
    <arm_group_label>pemetrexed maintenance</arm_group_label>
    <other_name>Folvite</other_name>
    <other_name>FA-8</other_name>
    <other_name>FaLessa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin B12 Injection</intervention_name>
    <description>vitamin B12 1000 μg IM 7 days prior to treatment initiation and the end of treatment</description>
    <arm_group_label>pemetrexed maintenance</arm_group_label>
    <other_name>Vitabee 12</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 4 mg twice orally for 3 days beginning the day before treatment until the end of treatment to minimize cutaneous reactions</description>
    <arm_group_label>pemetrexed maintenance</arm_group_label>
    <other_name>decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmation urothelial cancer of bladder, ureter, or
             renal pelvis.

          2. Patients must present with locally advanced, recurrent or metastatic disease not
             amenable to surgery, radiotherapy, or combined modality therapy with curative intent.

          3. Patients who were administered 4-6 cycles of cisplatin-based first line chemotherapy
             [GP (gemcitabine/cisplatin), classic MVAC
             (methotrexate/vinblastine/doxorubicin/cisplatin), or dose-dense MVAC] and were planned
             to undergo regular surveillance

          4. ce after confirmation of absence of disease progression on CT taken within 3 week
             after the administration of the last cycle of 1st line chemotherapy.

          5. For patients with recurrent disease who received prior adjuvant or neoadjuvant
             chemotherapy with cisplatin-containing regimen, the last administration of previous
             treatment should be administered at least 6 months before start date of 1st line
             chemotherapy.

          6. Measurable disease according RECIST criteria v 1.1.

          7. Age 20 years or older

          8. ECOG performance status 2 or better

          9. Adequate bone marrow, hepatic, and renal function

         10. Signed and dated informed consent of document indicating that the patient (or legally
             acceptable representative) has been informed of all pertinent aspects of the trial
             prior to enrollment

        Exclusion Criteria:

          1. Prior systemic chemotherapy or immunotherapy for palliative aim before or after 1st
             line cisplatin-based chemotherapy. However, prior intravesical chemotherapy or
             immunotherapy is allowed.

          2. Disease progression during or after 1st line cisplatin-based chemotherapy

          3. Known CNS metastasis

          4. Diagnosis of any serious secondary malignancy within the last 2 years, except for
             adequately treated basal cell or squamous cell carcinoma of skin, early gastric
             carcinoma, early stage thyroid carcinoma, insignificant prostate carcinoma, or in situ
             carcinoma of cervix uteri

          5. Pregnancy or breast feeding.

          6. Serious hypersensitivity reaction to pemetrexed.

          7. Severe renal function impairment with creatinine clearance 〈45 mL/min by standard
             Cockcroft-Gault formula or GFR measured by Tc99m-DPTA serum clearance method.

          8. Other severe acute or chronic medical or psychiatric condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Lyun Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jae-Lyun Lee, MD, PhD</last_name>
    <phone>82 2 3010 5977</phone>
    <email>jaelyun@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MiRan Kim</last_name>
    <phone>82 2 3010 5576</phone>
    <email>crnonc12@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hallym University Medical Center, Hallym University College of Medicine</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho Young Kim</last_name>
      <email>ksfam@daum.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keimyeong University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Young Kim, MD</last_name>
      <email>takgu@dsmc.or.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fatima Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung Lim Lee</last_name>
      <email>junglim3@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungnam University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo Jin Lee, MD, PhD.</last_name>
      <email>cymed@cnu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Health Insurance Service Ilsan Hospital</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo Jung Hong</last_name>
      <email>suzzy901@nhimc.or.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hallym University Dongtan Sacred Heart Hospital</name>
      <address>
        <city>Hwaseong-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Ae Jung</last_name>
      <email>hyunaejung@hallym.or.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inkeun Park, MD</last_name>
      <email>ingni79@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dong-A University Medical Center</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suee Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Il-Hwan Kim</last_name>
      <email>onelement@daum.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital, Pusan National University School of Medicine</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo Jung Kim</last_name>
      <email>leonkim80@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae-Lyun Lee, MD, PhD</last_name>
      <phone>82 2 3010 5977</phone>
      <email>jaelyun@amc.seoul.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chung Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee Joon Kim, MD</last_name>
      <email>heejun.dino11@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Sanggye Paik Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byeong Seok Sohn</last_name>
      <email>imbs@paik.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun-Gyoo Lee</last_name>
      <email>gosciny@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoon Ji Choi</last_name>
      <email>yoonji23@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhum Suk Keam</last_name>
    </contact>
    <contact_backup>
      <email>bhumsuk@snu.ac.kr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In-Ho Kim</last_name>
      <email>ihkmd@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yonsei Cancer Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Joon Shin</last_name>
      <email>ssj338@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital, The Catholic University of Korea</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byoung Yong Shim</last_name>
      <email>shimby@catholic.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uijeongbu St Mary's hospital, Catholic university of Korea</name>
      <address>
        <city>Uijeongbu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoon Ho Ko</last_name>
      <email>koyoonho@catholic.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwonoh Park</last_name>
      <email>parkkoh@hanmail.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000 Sep;18(17):3068-77.</citation>
    <PMID>11001674</PMID>
  </results_reference>
  <results_reference>
    <citation>Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Aug 10;31(23):2895-902. doi: 10.1200/JCO.2012.47.1102. Epub 2013 Jul 8.</citation>
    <PMID>23835707</PMID>
  </results_reference>
  <results_reference>
    <citation>Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009 Sep 20;27(27):4454-61. doi: 10.1200/JCO.2008.20.5534. Epub 2009 Aug 17. Erratum in: J Clin Oncol. 2010 Jan 1;28(1):182. Winquist, Eric [added].</citation>
    <PMID>19687335</PMID>
  </results_reference>
  <results_reference>
    <citation>Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol. 2002 Feb 15;20(4):937-40.</citation>
    <PMID>11844814</PMID>
  </results_reference>
  <results_reference>
    <citation>Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ, Kaufman DS. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006 Jul 20;24(21):3451-7.</citation>
    <PMID>16849761</PMID>
  </results_reference>
  <results_reference>
    <citation>Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Pond G, Godbold J, Oh WK, Bamias A. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. Urol Oncol. 2014 Jan;32(1):48.e1-8. doi: 10.1016/j.urolonc.2013.07.001. Epub 2013 Sep 18.</citation>
    <PMID>24055428</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2016</study_first_submitted>
  <study_first_submitted_qc>June 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2017</study_first_posted>
  <last_update_submitted>June 18, 2017</last_update_submitted>
  <last_update_submitted_qc>June 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>JLee</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Ureteral Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

